2.1 Genomic Profiling

Proprietary Sequencing

A new approach to next-generation sequencing

We give doctors access to a variety of sequencing capabilities, all with full transcriptome and tumor/normal match. We partner with physicians and hospitals to augment a hospital's current offering by providing access to Next Generation Sequencing with cutting-edge analytics and an interactive machine learning platform that also leverages data across our platform.


Targeted Panel of 648 genes

Enriched for clinically relevant genes and genes of emerging clinical relevance

Learn more


Whole Exome of ~20,000 genes

Providing the broadest genomic coverage for analysis

Download validation summary


Targeted Panel of 105 genes

Designed to detect actionable oncological targets in plasma

Learn more


Targeted panel of 15 genes

Whole exome architecture

Learn more


Capable of analyzing and reporting on individual genes with clinical significance for specific cancer subtypes.

DNA sequencing using tumor/normal match

Utilizing our proprietary xT and xE assays, we perform a tumor/normal matched analysis by sequencing both a tumor DNA sample and a normal DNA sample (blood or saliva) to ensure that your report accurately distinguishes between your patient’s somatic and germline variants.

RNA sequencing

Utilizing our proprietary RNA extraction protocols, we perform high-quality RNA sequencing on all samples we sequence through our xT and xE panels, where specimen quality and quantity allow. Profiling of the whole RNA transcriptome provides molecular information that is complementary to DNA sequencing and can be clinically important. This allows for clinically validated unbiased translocation detection.

Auto-conversion option to liquid biopsy

Through a simple automatic conversion selection, a biopsy-based Tempus|xT test can be converted to a blood-based Tempus|xF test in the event of an insufficient tumor tissue sample.

The tempus SEQUENCING lab

Bringing data and technology into clinical care

We've built a state-of-the-art, CAP-accredited and CLIA-certified lab. Our highly robotic laboratory is optimized for high-throughput clinical next-generation sequencing with a current capacity of over 100,000 patients annually. Sequencing is completed within two to three weeks of receiving patient samples.

Download our lab overview


The Benefits of Combining Molecular and Clinical Data for Patients

“Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials […] and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.”

Learn more about the xT 500 Publication in Nature Biotechnology

Combined DNA and RNA sequencing using Tempus|xT increased the high level therapy matching rate to 43.4% of patients.

Follow-Up Testing Covered Under Tempus Financial Assistance*

Any patients who receive Tempus testing may apply for Tempus’ Financial Assistance Program. If approved, the Program covers all Tempus|xF (liquid) or Tempus|xT (solid) testing within 18 months of Program approval. All U.S.-based patients may qualify.

* Tempus testing is always conducted based on the medical judgement of an ordering physician.

Get in touch with us.

Contact Us